Health and Healthcare
Agilent Beats on Profits, but Guidance Does Not Match Analyst Expectations
Published:
Last Updated:
Third-quarter orders dropped 6% year-over-year to $953 million. Adjusted to exclude the impact of currency exchange rates, the NMR business and acquisitions and divestitures in the past 12 months, orders rose 3% and revenues rose 9%.
The company’s CEO, Mike McMullen, said:
Agilent delivered excellent results for our shareholders in the third quarter. Revenue was at the high end of our guidance, and earnings per share were above our guidance range. Our operating model is driving above-market revenue growth and margin expansion. In Q3, we delivered an adjusted operating margin of 19.9 percent(4), up 110 basis points from last year.
Agilent expects fourth-quarter 2015 revenue in the range of $1.03 billion to $1.05 billion. Fourth-quarter non-GAAP earnings are expected to be in the range of $0.45 to $0.49 per share. Consensus estimates call for EPS of $0.50 on revenues of $1.06 billion
For fiscal year 2015, Agilent forecast revenue of $4.03 billion to $4.05 billion and non-GAAP earnings of $1.68 to $1.72 per share. Â Analysts are looking for EPS of $1.70 on revenues of $4.06 billion.
In Monday’s after-hours session, Agilent shares traded down about 0.2% at $38.76 after closing the regular trading session up 0.44% at $38.82. The stock’s 52-week range is $35.62 to $43.59. The consensus price target is $45.50.
ALSO READ: The Next 11 States to Legalize Marijuana
Warren Buffett loves dividend stocks, and has stuffed Berkshire with some of his favorites.
But he overlooked two dividend legends that continue to print checks on a new level, they’re nowhere in his portfolio.
Unlock the two dividend legends Buffett missed in this new free report.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.